CDT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CDT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Conduit Pharmaceuticals's Enterprise Value is $206.91 Mil. Conduit Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $0.71 Mil. Therefore, Conduit Pharmaceuticals's EV-to-EBIT ratio for today is 291.84.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Conduit Pharmaceuticals's Enterprise Value is $206.91 Mil. Conduit Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $0.71 Mil. Therefore, Conduit Pharmaceuticals's EV-to-EBITDA ratio for today is 291.84.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Conduit Pharmaceuticals's Enterprise Value is $206.91 Mil. Conduit Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil. Therefore, Conduit Pharmaceuticals's EV-to-Revenue ratio for today is .
The historical data trend for Conduit Pharmaceuticals's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Conduit Pharmaceuticals Annual Data | |||||||
Trend | Dec21 | Dec22 | Dec23 | ||||
Enterprise Value | - | - | 332.68 |
Conduit Pharmaceuticals Quarterly Data | ||||||||
Dec21 | Mar22 | Sep22 | Dec22 | Mar23 | Sep23 | Dec23 | Mar24 | |
Enterprise Value | Get a 7-Day Free Trial | - | - | 427.04 | 332.68 | 270.41 |
For the Biotechnology subindustry, Conduit Pharmaceuticals's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Conduit Pharmaceuticals's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Conduit Pharmaceuticals's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Conduit Pharmaceuticals's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
Enterprise Value (A: Dec. 2023 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 335.924225 | + | 0 | + | 0 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 0.985 | + | 0 | - | 4.228 |
= | 332.68 |
Conduit Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2024 is calculated as
Enterprise Value (Q: Mar. 2024 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 270.954265 | + | 0 | + | 0.171 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 1.124 | + | 0 | - | 1.844 |
= | 270.41 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Conduit Pharmaceuticals (NAS:CDT) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Conduit Pharmaceuticals's EV-to-EBIT for today is
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | 206.912 | / | 0.709 | |
= | 291.84 |
Conduit Pharmaceuticals's current Enterprise Value is $206.91 Mil.
Conduit Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.71 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Conduit Pharmaceuticals's EV-to-EBITDA for today is:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA(TTM) |
= | 206.912 | / | 0.709 | |
= | 291.84 |
Conduit Pharmaceuticals's current Enterprise Value is $206.91 Mil.
Conduit Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.71 Mil.
3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.
Conduit Pharmaceuticals's EV-to-Revenue for today is:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 206.912 | / | 0 | |
= |
Conduit Pharmaceuticals's current Enterprise Value is $206.91 Mil.
Conduit Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Conduit Pharmaceuticals's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Intelmed Llc | other: See Responses | 11421 GOLDEN EAGLE COURT, NAPLES FL 34120 |
Jennifer Isacoff Mcnealey | director | C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO Z4 92121 |
David Tapolczay | director, officer: Chief Executive Officer | 32 CROUCH HALL LANE, ST. ALBANS X0 AL3 7EU |
Andrew Regan | director, 10 percent owner | LE MANOIR DE LURIN, SAINT BARTHELEMY Z0 97133 |
Faith L. Charles | director | ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019 |
Algo Holdings, Inc. | 10 percent owner, other: See Responses | 100 W. CYPRESS CREEK ROAD, STE. 640, FORT LAUDERDALE NY 33309 |
Corvus Capital Ltd. | 10 percent owner, other: See Responses | WILLOW HOUSE, CRICKET SQUARE PO BOX 709, GRAND CAYMAN E9 KY1 - 1107 |
Freda C Lewis-hall | director | C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139 |
James Bligh | director | 38 OXBERRY AVENUE, LONDON X0 SW6 5SS |
Shaolin Capital Management Llc | 10 percent owner | 230 NW 24TH STREET, SUITE 603, MIAMI FL 33127 |
Richard Edward Feinberg | director | 2855 FIFTH AVENUE, UNIT 405, SAN DIEGO CA 92103 |
Murphy Canyon Acquisition Sponsor, Llc | 10 percent owner | 4995 MURPHY CANYON ROAD, SUITE 300, SAN DIEGO CA 92123 |
Chele Chiavacci Farley | director | 4 RIDGE ROAD, TUXEDO PARK NY 10987 |
Bentzen Edwin H Iv | officer: Chief Accounting Officer | 2513 BIRCH HOLLOW ST, HENDERSON NV 89044 |
Jack Kendrick Heilbron | director, officer: CEO, President, and Chairman | 16433 BRONCO LANE, POWAY CA 92064 |
From GuruFocus
By Marketwired • 11-02-2023
By Marketwired • 09-22-2023
By Marketwired • 10-11-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.